SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
AMPK
NAFLD
SGLT2 inhibitors
cardiovascular
diabetes
kidney
Journal
Cell biochemistry and function
ISSN: 1099-0844
Titre abrégé: Cell Biochem Funct
Pays: England
ID NLM: 8305874
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
20
12
2023
received:
22
09
2023
accepted:
29
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
ppublish
Résumé
Sodium-glucose co-transporter-2 (SGLT2) inhibitors, known as Gliflozins, are a class of Glucose-lowering drugs in adults with type 2 diabetes (T2D) that induce glucosuria by blocking SGLT2 co-transporters in the proximal tubules. Several lines of evidence suggest that SGLT2 inhibitors regulate multiple mechanisms associated with the regulation of varying cellular pathways. The 5'-adenosine monophosphate-activated protein kinase (AMPK) pathway plays an important role in metabolic homeostasis by influencing cellular processes. Recently, it has been shown that SGLT2 inhibitors can affect the AMPK pathway in differing physiological and pathological ways, resulting in kidney, intestinal, cardiovascular, and liver protective effects. Additionally, they have therapeutic effects on nonalcoholic fatty liver disease and diabetes mellitus-associated complications. In this review, we summarize the results of studies of AMPK-associated therapeutic effects of SGLT2 inhibitors in different organelle functions.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3922Subventions
Organisme : Cardiovascular Research Center, Tabriz University of Medical Sciences
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Khunti K, Jabbour S, Cos X, et al. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab. 2022;24(7):1187-1196.
Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine. 2016;53:364-372.
Ataei S, Kesharwani P, Sahebkar A. Berberine: ins and outs of a nature-made PCSK9 inhibitor. EXCLI J. 2022;21:1099-1110.
Belančić A, Klobučar S. Sodium-glucose co-transporter 2 inhibitors as a powerful cardioprotective and renoprotective tool: overview of clinical trials and mechanisms. Diabetology. 2023;4(3):251-258.
Kochanowska A, Rusztyn P, Szczerkowska K, et al. Sodium-glucose cotransporter 2 inhibitors to decrease the uric acid concentration-a novel mechanism of action. J Cardiovasc Dev Dis. 2023;10(7):268.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33-59.
Viollet B. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci. 2009;14:3380.
Carman L. Measuring AMPK activity in vivo using a genetically-encoded biosensor. Saint Joseph's University; 2023.
Zheng A, Kwak SE, Birk JB, et al. Greater phosphorylation of AMPK and multiple AMPK substrates in the skeletal muscle of 24-month-old calorie restricted compared to ad-libitum fed male rats. J Gerontol A. 2023;78(2):177-185.
Cui Y, Chen J, Zhang Z, Shi H, Sun W, Yi Q. The role of AMPK in macrophage metabolism, function and polarisation. J Transl Med. 2023;21(1):892.
Wang L, Hu J, Zhou H. Macrophage and adipocyte mitochondrial dysfunction in obesity-induced metabolic diseases. World J Mens Health. 2021;39(4):606.
Packer M. Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors. J Am Soc Nephrol. 2020;31(5):907-919.
Packer M. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: a novel conceptual framework. Diabetes, Obes Metab. 2020;22(5):734-742.
Faridvand Y, Kazemzadeh H, Vahedian V, et al. Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation. Clin Exp Pharmacol Physiol. 2022;49(6):643-651.
Hoong CWS, Chua MWJ. SGLT2 inhibitors as calorie restriction mimetics: insights on longevity pathways and age-related diseases. Endocrinology. 2021;162(8):bqab079.
Hawley SA, Ford RJ, Smith BK, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784-2794.
Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
Lee J-Y, Lee M, Lee JY, et al. Ipragliflozin, an SGLT2 inhibitor, ameliorates high-fat diet-induced metabolic changes by upregulating energy expenditure through activation of the AMPK/SIRT1 pathway. Diabetes Metab J. 2021;45(6):921-932.
Packer M. Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circ Heart Fail. 2020;13(9):e007197.
Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335-346.
Gronda E, Napoli C, Iacoviello M, et al. ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. Eur Heart J Suppl. 2021;23(suppl C):C184-C195.
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215-225.
Kaneto H, Obata A, Kimura T, et al. Unexpected pleiotropic effects of SGLT2 inhibitors: pearls and pitfalls of this novel antidiabetic class. Int J Mol Sci. 2021;22(6):3062.
Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87.
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.
Chadchan SB, Popli P, Ambati CR, et al. Gut microbiota-derived short-chain fatty acids protect against the progression of endometriosis. Life Sci Alliance. 2021;4:e202101224.
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11-26.
Feder D, de Fatima Veiga Gouveia MR, Govato TCP, Nassis CDZ. SGLT2 inhibitors and the mechanisms involved in weight loss. Curr Pharmacol Rep. 2020;6:346-353.
Endris T, Worede A, Asmelash D. Prevalence of diabetes mellitus, prediabetes and its associated factors in Dessie Town, Northeast Ethiopia: a community-based study. Diabetes Metab Syndr Obes. 2019;12:2799-2809.
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
Ashraf H, Soltani D, Sobh-Rakhshankhah A, et al. Visfatin as marker of isolated coronary artery ectasia and its severity. Cytokine. 2019;113:216-220.
Hsiang JC, Wong VW-S. SGLT2 inhibitors in liver patients. Clin Gastroenterol Hepatol. 2020;18(10):2168-2172.
Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021;2(12):2027-2037.
Johal G, Jonnala V, Pourafkari L, et al. Energy loss index as a predictor of all-cause mortality after transcatheter aortic valve replacement: a long-term follow-up. Echocardiography. 2023;40(4):327-334.
Entezari M, Hashemi D, Taheriazam A, et al. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: a pre-clinical and clinical investigation. Biomed Pharmacother. 2022;146:112563.
Misquitta NS, Ravel-Chapuis A, Jasmin BJ. Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner. Hum Mol Gen. 2023;32(4):551-566.
Kurkin DV, Morkovin EI, Bakulin DA, et al. Modern concepts of the pathogenesis of type 2 diabetes mellitus. J Volgogr State Med Univ. 2022;19(4):34-49.
Rehman SU, Rahman F. Evidence-based clinical review on cardiovascular benefits of SGLT2 (sodium-glucose co-transporter type 2) inhibitors in type 2 diabetes mellitus. Cureus. 2020;12:8.
Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine. 2019;47(1):22-27.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-772.
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117.
Mohebi R, Januzzi JL. Cardiovascular benefit of SGLT2 inhibitors. Crit Rev Clin Lab Sci. 2022;59(3):142-155.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.
Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. 2020;13:161-174.
Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells. 2021;10(8):2150.
Hoffman JI, Buckberg GD. The myocardial oxygen supply: demand index revisited. J Am Heart Assoc. 2014;3(1):e000285. doi:10.1161/JAHA.113.000285
Wu S, Zou M-H. AMPK, mitochondrial function, and cardiovascular disease. Int J Mol Sci. 2020;21(14):4987.
Song P, Zou M-H. Regulation of NAD (P) H oxidases by AMPK in cardiovascular systems. Free Radic Biol Med. 2012;52(9):1607-1619.
Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol. 2020;6:9.
Younossi ZM, Golabi P, de Avila L, et al. The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: a systematic review and meta-analysis. Short Title: global prevalence of NAFLD and NASH in T2DM. J Hepatol. 2019;71(4):793-801.
Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-595.
Shao S-C, Kuo L-T, Chien R-N, Hung M-J, Lai EC-C. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care. 2020;8(2):e001956.
Soltani D, Jafari S, Ashraf H, et al. Ratio of serum aspartate to alanine aminotransferase as a marker of isolated coronary artery ectasia and its severity. Heart Int. 2020;14(1):43.
Yabiku K. Efficacy of sodium-glucose cotransporter 2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic steatohepatitis: a review of the evidence. Front Endocrinol. 2021;12:1682.
Zhang Y, Liu X, Zhang H, Wang X. Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol. 2022;12:13.
Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37:4697-4708.
Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12:843-861.
Osataphan S, Macchi C, Singhal G, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms. JCI Insight. 2019;4(5):e123130.
Shi M, Zhang H, Wang W, et al. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complications. 2023;37(10):108610.
Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 inhibitors as the most promising influencers on the outcome of non-alcoholic fatty liver disease. Int J Mol Sci. 2022;23(7):3668.
Androutsakos T, Nasiri-Ansari N, Bakasis A-D, et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022;23(6):3107.
Gao W, Zhao Y, Guo L, et al. Comparative effectiveness of glycyrrhizic acid preparations aimed at improving liver function of patients with chronic hepatitis B: a network meta-analysis of 53 randomized controlled trials. Phytomedicine. 2023;116:154883.
Lee DH, Park JS, Lee YS, et al. SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity. Autophagy. 2020;16(11):1949-1973.
Zheng L, Yang W, Wu F, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 2013;19(19):5372-5380.
Pyun DH, Kim TJ, Park SY, et al. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation. Mol Cell Endocrinol. 2021;538:111464.
Fang C, Pan J, Qu N, et al. The AMPK pathway in fatty liver disease. Front Physiol. 2022;13:970292.
Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes, Obes Metab. 2019;21(5):1237-1250.
Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci. 2018;132(12):1329-1339.
Suganuma Y, Takahashi H, Ohno T, Nishimura R. 888-P: urinary albumin levels prior to SGLT2 inhibitors initiation predict increased TIR after 12 months in patients with type 1 diabetes on sensor-augmented pump therapy. Diabetes. 2023;72(suppl 1):888-P.
Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121(6):2181-2196.
Kogot-Levin A, Hinden L, Riahi Y, et al. Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors. Cell Rep. 2020;32(4):107954.
Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32(3):404-419.
Schaub JA, AlAkwaa FM, McCown PJ, et al. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J Clin Invest. 2023;133(5):e164486.
Heerspink H, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.
Juszczak F, Caron N, Mathew AV, Declèves A-E. Critical role for AMPK in metabolic disease-induced chronic kidney disease. Int J Mol Sci. 2020;21(21):7994.
Zhou X, Muise ES, Haimbach R, et al. PAN-AMPK activation improves renal function in a rat model of progressive diabetic nephropathy. J Pharmacol Exp Ther. 2019;371(1):45-55.
Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport. Diabetes Care. 2015;38(12):2344-2353.
Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079-2086.
Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Care. 2013;36(8):2154-2161.
Vanuytsel T, Tack J, Farre R. The role of intestinal permeability in gastrointestinal disorders and current methods of evaluation. Front Nutr. 2021;8:717925.
Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14(1):9-21.
Marr EE, Mulhern TJ, Welch M, et al. A platform to reproducibly evaluate human colon permeability and damage. Sci Rep. 2023;13(1):8922.
Horowitz A, Chanez-Paredes SD, Haest X, Turner JR. Paracellular permeability and tight junction regulation in gut health and disease. Nat Rev Gastroenterol Hepatol. 2023;20:1-16.
Fitzpatrick ER. Acute responses to infectious and inflammatory disorders of the gastrointestinal system. AACN Adv Crit Care. 2022;33(1):85-98.
Kałużna A, Olczyk P, Komosińska-Vassev K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J Clin Med. 2022;11(2):400.
Kim J, Kwak HJ, Cha J-Y, et al. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem. 2014;289(33):23246-23255.
Sun X, Zhu M-J. AMP-activated protein kinase: a therapeutic target in intestinal diseases. Open Biol. 2017;7(8):170104.
Xu T, Lu X, Arbab AAI, et al. Metformin acts to suppress β-hydroxybutyric acid-mediated inflammatory responses through activation of AMPK signaling in bovine hepatocytes. J Anim Sci. 2021;99(7):skab153.
Desai M, Fang R, Sun J. The role of autophagy in microbial infection and immunity. Immunotargets Ther. 2015;4:13-26.
Dumitru C, Kabat AM, Maloy KJ. Metabolic adaptations of CD4+ T cells in inflammatory disease. Front Immunol. 2018;9:540.
Serebrennikova SN. Inflammation as a fundamental pathological process: lecture 1 (alteration, vascular reactions). Baikal Med J. 2023;2(2):53-64.
Yue T, Wang X, Zhao M, Weng J, Luo S, Zheng X. 1362-P: the long-term cardiovascular effects of metformin on patients with newly diagnosed type 2 diabetes. Diabetes. 2023;72(suppl 1):1362-P.
Kuhre RE, Deacon CF, Wewer Albrechtsen NJ, Holst JJ. Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production? Diabetes, Obes Metab. 2021;23(9):2009-2019.
Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146(18):1383-1405.